SCHEMBL27209645

SCHEMBL27209645

CCOCn1nc(C(F)(F)F)cc1C(=O)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.40
▸ TP53 P04637 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ HPGD P15428 3/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ POLB P06746 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ GAA P10253 2/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ KLKB1 P03952 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ALPL P05186 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18695272 0.74 TP53 (0.45) LMNATP53L3MBTL1KDM4EHPGD
SCHEMBL950947 0.70 GRN (0.49) LMNATP53L3MBTL1KDM4EALDH1A1
SCHEMBL28013854 0.69 LMNA (0.45) LMNATP53L3MBTL1KDM4EALDH1A1
SCHEMBL22067596 0.69 TP53 (0.40) LMNATP53L3MBTL1KDM4EPOLB
SCHEMBL13169995 0.69 HPGD (0.47) LMNATP53L3MBTL1KDM4EHPGD
SCHEMBL10447771 0.68 GRN (0.51) LMNATP53L3MBTL1KDM4EALDH1A1
SCHEMBL22637243 0.68 HPGD (0.44) LMNATP53L3MBTL1KDM4EHPGD
SCHEMBL3711515 0.67 NPC1 (0.48) LMNATP53KDM4EHPGDALDH1A1
SCHEMBL22637689 0.67 KDM4E (0.52) LMNATP53L3MBTL1KDM4EHPGD
SCHEMBL18695261 0.67 TP53 (0.49) LMNATP53L3MBTL1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595239-B2 Substituted isoxazoline derivatives BASF SE (DE) 2026-04-07 — — US disclosed
EP-4291551-B1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2025-08-13 — — EP disclosed
US-20240140917-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2024-05-02 — — US disclosed
EP-4291551-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2023-12-20 — — EP disclosed
WO-2022171472-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2022-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595239-B2 Substituted isoxazoline derivatives CBR3, ADRA2C, CYP4Z1 LMNA 1414/4885TP53 4755/4885L3MBTL1 181/4885
US-20240140917-A1 SUBSTITUTED ISOXAZOLINE DERIVATIVES CYP4X1, PRDX5, PRDX1 LMNA 3180/4885TP53 4468/4885L3MBTL1 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback